Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer

5 ноября 2026 г. обновлено: Zhongguang Luo, MD, Huashan Hospital

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer : A Phase Il Study

To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) in resectable locally advanced gastric cancer.

Обзор исследования

Статус

Рекрутинг

Условия

Вмешательство/лечение

Подробное описание

This is a single-arm clinical study to enroll 50 patients with gastric cancer (cTNM diagnosis of cT3-4aN1-3M0). Each enrolled patient will be assigned a case number. Both this case number and the patient's initials will be entered on each page of the case report form.

Enrolled patients receive a neoadjuvant regimen of POLF in combination with sindilizumab: preoperatively, they receive a POLF regimen (paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, and 5-fluorouracil 425 mg/m2) administered once weekly for a total of 6 doses, and in combination with sindilizumab 200 mg intravenously once every 3 weeks for a total of 2 doses. Upon completion of the evaluation, patients whose tumors were judged to be resectable underwent radical surgery and received six postoperative doses of the POLF regimen and two doses of Sindilizumab as adjuvant therapy.

Postoperative imaging evaluations will be performed every three months until disease recurrence. Survival follow-up was performed every three months after disease recurrence. Patients will receive neoadjuvant therapy for 6 weeks preoperatively and adjuvant therapy for 6 weeks postoperatively unless intolerable toxicity occurs, the patient refuses to continue treatment, or treatment is delayed beyond 3 weeks. Patients will be under study observation during treatment and 30 days after treatment termination, and will receive long-term follow-up for 5 years postoperatively. Ultimately, pCR and MPR will be the primary study endpoints, and ORR, DCR, 2-year PFS rate, 3-year OS rate and safety will be the secondary study endpoints to evaluate the efficacy and safety of the neoadjuvant regimen of POLF combined with sindilizumab, as well as to explore the immune activation effect and mechanism of the regimen using peripheral blood and tumor tissue samples.

Тип исследования

Интервенционный

Регистрация (Оцененный)

50

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Shanghai, Китай
        • Рекрутинг
        • Huashan Hospital, Fudan University
        • Контакт:
          • Wanwei Zheng
          • Номер телефона: +86 13816431448
          • Электронная почта: calebzww@yeah.net

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Signed written Informed Consent Form

  2. Male or female, age ≥ 18 years old

  3. Histologically confirmed gastric adenocarcinoma, diagnosed as locally progressive according to the AJCC 8th ed, cTNM diagnosis of cT3-4aN1-3M0 and resectable lesion as assessed by the investigator

  4. No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand

  5. Consent to radical surgical treatment and no contraindications to surgery as determined by the surgeon

  6. ECOG PS: 0-1 score

  7. Expected survival > 6 months

  8. Adequate organ function, must meet the following laboratory specifications:

    8.1 Absolute neutrophil count (ANC) ≥ 1.0x10^9/L; 8.2 Platelets ≥ 80x10^9/L; 8.3 Hemoglobin > 7g/dL; 8.4 Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Total bilirubin > 1.5 x ULN but direct bilirubin ≤ ULN are allowed to be enrolled); 8.5 AST, ALT ≤ 2.5×ULN; 8.6 Blood creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 ml/min; 8.7 INR or PT ≤ 1.5 times ULN; 8.8 TSH within normal range (Enrollment allowed if baseline TSH is outside normal range but FT4 is within normal range); 8.9 Myocardial enzyme profile within normal range;

  9. Negative pregnancy test in women of childbearing age

  10. Need to use contraception with an annual failure rate of less than 1% if there is a risk of conception

Exclusion Criteria:

  1. Endoscopically show signs of active bleeding from the lesion
  2. Current participation in an interventional clinical study or treatment with another investigational drug or use of an investigational device within 4 weeks prior to the first dose of study drug
  3. Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or agents targeting CTLA-4, OX-40, CD137, etc.
  4. Diagnosis of a malignant disease other than gastric cancer within 5 years prior to the first dose of therapy
  5. Active autoimmune disease requiring systemic therapy within 2 years prior to the first dose of the drug
  6. Live vaccination within 30 days prior to the first administration of the drug
  7. Have received systemic systemic therapy with proprietary Chinese medicines with antitumor indications or immunomodulatory drugs within 2 weeks prior to the first administration of the drug
  8. Have received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment
  9. Has not fully recovered from any intervention-induced toxicity and/or complications (excluding malaise or alopecia) prior to initiation of therapy
  10. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
  11. Known hypersensitivity to drugs used in this study
  12. Known history of HIV infection
  13. Untreated active hepatitis B
  14. Active HCV infection
  15. Pregnant or lactating women
  16. The presence of any serious or uncontrolled systemic disease
  17. Other factors that, in the judgment of the investigator, may affect the outcome of the study

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Н/Д
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: sintilimab+metronomic POLF

Sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and POLF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) followed by adjuvant sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and POLF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)

Drug: Sintilimab 200mg iv d1 Q3W, 2cycles

Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles

Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles

Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of participants with no residual surviving tumor cells in resection specimens and lymph nodes
Временное ограничение: up to 6 weeks after first dosing

Pathological complete response rate (pCR), defined as the proportion of participants with no residual viable tumor cells on microscopy and negative lymph nodes as a percentage of all participants. We will evaluate pathological complete response rate of primary tumor and locally metastatic lymph nodes after 6 weeks of neoadjuvant therapy.

up to 6 weeks after first dosing
Percentage of participants with ≤10% tumor cell survival in resection specimens
Временное ограничение: up to 6 weeks after first dosing

Major pathologic response (MPR) rate, defined as the proportion of participants with ≤10% surviving tumor cells in the resection specimen as a percentage of all participants. We will evaluate major pathological response rate of primary tumor and locally metastatic lymph nodes after 6 weeks of neoadjuvant therapy.

up to 6 weeks after first dosing

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of participants achieving complete remission (CR) and partial remission (PR) after treatment
Временное ограничение: 2 to 6weeks after the end of treatment

Objective remission rate (ORR), the percentage of participants whose tumors shrink by a certain amount and remain there for a certain period of time, including complete remission (CR) and partial remission (PR). CR (Complete remission): Complete disappearance of the target lesion, with no new lesions produced, and lasting for more than 4 weeks. PR (Partial remission): the sum of the largest diameters of the target lesions is reduced by more than 30%, and lasts for more than 4 weeks.

2 to 6weeks after the end of treatment
Percentage of participants achieving remission (PR+CR) and lesion stabilization (SD) after treatment
Временное ограничение: 2 to 6weeks after the end of treatment

Disease control rate (DCR) is the percentage of participants who achieve remission (PR+CR) and stabilization of lesions (SD) after the treatment. Stable disease (SD) means that the sum of the largest diameters of the tumor lesions has not shrunk to PR, or has not enlarged to PD.

2 to 6weeks after the end of treatment
2-year progression-free survival (PFS) rate
Временное ограничение: From enrollment to study completion, assessed up to 2 years

Percentage of participants who survived or were free of tumor progression from enrollment to the second year of follow-up.

From enrollment to study completion, assessed up to 2 years
3-year overall-survival (OS) rate
Временное ограничение: From enrollment to study completion, assessed up to 3 years

Percentage of participants who survived from enrollment to the third year of follow-up.

From enrollment to study completion, assessed up to 3 years
Number of participants with treatment-related adverse events as assessed by NCI-CTC
Временное ограничение: From enrollment to study completion, assessed up to 3 years

Toxicity deaths and early withdrawal from treatment due to toxic effects will be described. Toxicity assessment of adverse events and serious adverse events (SAEs) using the NCI-CTC.

From enrollment to study completion, assessed up to 3 years

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
Number of immune cells in peripheral blood
Временное ограничение: From enrollment to study completion, assessed up to 3 years

Peripheral blood will be analyzed for the number of immune cells after applying flow cytometry and mRNA sequencing.

From enrollment to study completion, assessed up to 3 years
Proportion of immune cells in peripheral blood
Временное ограничение: From enrollment to study completion, assessed up to 3 years

Peripheral blood will be analyzed for the proportion of immune cells after applying flow cytometry and mRNA sequencing.

From enrollment to study completion, assessed up to 3 years
Number of immune cells in tumor tissues
Временное ограничение: From enrollment to study completion, assessed up to 3 years

Apply mRNA sequencing, immunohistochemistry and immunofluorescence to analyze the number of immune cells in tumor tissues, including CTL, Treg, DC, TAM, MDSC, NK, NKT and so on.

From enrollment to study completion, assessed up to 3 years
Distribution of immune cells in tumor tissue
Временное ограничение: From enrollment to study completion, assessed up to 3 years

Apply mRNA sequencing, immunohistochemistry and immunofluorescence to analyze the distribution of immune cells in tumor tissues, including CTL, Treg, DC, TAM, MDSC, NK, NKT and so on.

From enrollment to study completion, assessed up to 3 years

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

18 октября 2023 г.

Первичное завершение (Оцененный)

30 декабря 2026 г.

Завершение исследования (Оцененный)

31 декабря 2026 г.

Даты регистрации исследования

Первый отправленный

12 сентября 2023 г.

Впервые представлено, что соответствует критериям контроля качества

22 сентября 2023 г.

Первый опубликованный (Действительный)

26 сентября 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

10 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

5 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

продукт, произведенный в США и экспортированный из США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться